@article{eac0ec123156440b8068e42a188ef915,
title = "Reply to {\textquotedblleft}Anti-IL5/IL5R switching between biologics in patients with severe eosinophilic asthma{\textquotedblright}",
author = "Katrien Eger and Kroes, \{Johannes A.\} and \{ten Brinke\}, Anneke and Bel, \{Elisabeth H.\}",
note = "Funding Information: No funding was received for this work. Conflicts of interest: A. ten Brinke reports institutional grants from GSK, TEVA, and AstraZeneca outside the submitted work and participated in advisory boards for AstraZeneca, TEVA, and Sanofi Regeneron. J. A. Kroes reports a grant from AstraZeneca. E. H. Bel reports institutional grants from GSK and TEVA; consulting fees from GSK, AstraZeneca, Sanofi, and Chiesi; honorarium for chairing a session from TEVA; and participation on an Advisory Board for AstraZeneca. K. Eger declares that she has no relevant conflicts of interest.",
year = "2022",
month = jul,
day = "1",
doi = "10.1016/j.jaip.2022.04.018",
language = "English",
volume = "10",
pages = "1936",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "American Academy of Allergy, Asthma and Immunology",
number = "7",
}
SDG 3 Good Health and Well-being